The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation
Open accessAbstract
OBJECTIVES: To review the clinical effectiveness and cost-effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDs) (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis (OA) and rheumatoid arthritis (RA). DATA SOURCES: Electronic databases were searched up to November 2003. Industry submissions to the National Institute for Health and Clinical Excellence (NICE) in 2003 were also reviewed. REVIEW METHODS: Systematic reviews of randomised controlled trials (RCTs) and a model-based economic evaluation were undertaken. Meta-analyses were undertaken for each COX-2 selective NSAID compared with placebo and non-selective NSAIDs. The model was designed to run in two forms: the 'full Assessment Group Model (AGM)', which includes an initial drug switching cycle, and the 'simpler AGM', where there is no initial cycle and no opportunity for the patient to switch NSAID. RESULTS: Compared with non-selective NSAIDs, the COX-2 selective NSAIDs were found to be equally as efficacious as the non-selective NSAIDs (although meloxicam was found to be of inferior or equivalent efficacy) and also to be associated with significantly fewer clinical upper gastrointestinal (UGI) events (although relatively small numbers of clinical gastrointestinal (GI) and myocardial infarction (MI) events were reported across trials). Subgroup analyses of clinical and complicated UGI events and MI events in relation to aspirin use, steroid use, prior GI history and Helicobacter pylori status were based on relatively small numbers and were inconclusive. In the RCTs that included direct COX-2 comparisons, the drugs were equally tolerated and of equal efficacy. Trials were of insufficient size and duration to allow comparison of risk of clinical UGI events, complicated UGI events and MIs. One RCT compared COX-2 (celecoxib) with a non-selective NSAID combined with a gastroprotective agent (diclofenac combined with omeprazole); this included arthritis patients who had recently suffered a GI haemorrhage. Although no significant difference in clinical GI events was reported, the number of events was small and more such studies, where patients genuinely need NSAIDs, are required to confirm these data. A second trial showed that rofecoxib was associated with fewer diarrhoea events than a combination of diclofenac and misoprostol (Arthrotec). Previously published cost-effectiveness analyses indicated a wide of range of possible incremental cost per quality-adjusted life-year (QALY) gained estimates. Using the simpler AGM, with ibuprofen or diclofenac alone as the comparator, all of the COX-2 products are associated with higher costs (i.e. positive incremental costs) and small increases in effectiveness (i.e. positive incremental effectiveness), measured in terms of QALYs. The magnitude of the incremental costs and the incremental effects, and therefore the incremental cost-effectiveness ratios, vary considerably across all COX-2 selective NSAIDs. The base-case incremental cost per QALY results for COX-2 selective NSAIDs compared with diclofenac for the simpler model are: celecoxib (low dose) 68,400 pounds; celecoxib (high dose) 151,000 pounds; etodolac (branded) 42,400 pounds; etodolac (generic) 17,700 pounds; etoricoxib 31,300 pounds; lumiracoxib 70,400 pounds; meloxicam (low dose) 10,300 pounds; meloxicam (high dose) 17,800 pounds; rofecoxib 97,400 pounds; and valdecoxib 35,500 pounds. When the simpler AGM was run using ibuprofen or diclofenac combined with proton pump inhibitor (PPI) as the comparator, the results change substantially, with the COX-2 selective NSAIDs looking generally unattractive from a cost-effectiveness point of view (COX-2 selective NSAIDs were dominated by ibuprofen or diclofenac combined with PPI in most cases). This applies both to 'standard' and 'high-risk' arthritis patients defined in terms of previous GI ulcers. The full AGM produced results broadly in line with the simpler model. CONCLUSIONS: The COX-2 selective NSAIDs examined were found to be similar to non-selective NSAIDs for the symptomatic relief of RA and OA and to provide superior GI tolerability (the majority of evidence is in patients with OA). Although COX-2 selective NSAIDs offer protection against serious GI events, the amount of evidence for this protective effect varied considerably across individual drugs. The volume of trial evidence with regard to cardiovascular safety also varied substantially between COX-2 selective NSAIDs. Increased risk of MI compared to non-selective NSAIDs was observed among those drugs with greater volume of evidence in terms of exposure in patient-years. Economic modelling shows a wide range of possible costs per QALY gained in patients with OA and RA. Costs per QALY also varied if individual drugs were used in 'standard' or 'high'-risk patients, the choice of non-selective NSAID comparator and whether that NSAID was combined with a PPI. With re
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Meta-analysis: Principles and procedures
Egger, M., Smith, G. D., & Phillips, A. N. (1997) · BMJ · doi:10.1136/bmj.315.7121.1533 · Cited by 2,415
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs
Wolfe, M. M., Lichtenstein, D. R., & Singh, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402407 · Cited by 1,956
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
Gabriel, S. E., Jaakkimainen, L., & Bombardier, C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-10-787 · Cited by 1,237
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Silverstein, F. E., Graham, D. Y., Senior, J. R., Davies, H. W., Struthers, B. J., Bittman, R. M., & Geis, G. S. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-4-199508150-00001 · Cited by 1,059
García Rodríguez, L., & Jick, H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91843-0 · Cited by 975
NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
Wallace, J. L., McKnight, W., Reuter, B. K., & Vergnolle, N. (2000) · Gastroenterology · doi:10.1053/gast.2000.16510 · Cited by 705
Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16893-1 · Cited by 701
Adverse Upper Gastrointestinal Effects of Rofecoxib Compared With NSAIDs
Langman, M. J. (1999) · JAMA · doi:10.1001/jama.282.20.1929 · Cited by 686
Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis
Derry, S. (2000) · BMJ · doi:10.1136/bmj.321.7270.1183 · Cited by 677
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century
Symmons, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.7.793 · Cited by 646
Lai, K. C., Lam, S. K., Chu, K. M., Wong, B. C. Y., Hui, W. M., Hu, W. H. C., Lau, G. K. K., Wong, W. M., Yuen, M. F., Chan, A. O. O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012877 · Cited by 646
Chan, F. K. L., Hung, L. C. T., Suen, B. Y., Wu, J. C. Y., Lee, K. C., Leung, V. K. S., Hui, A. J., To, K. F., Leung, W. K., Wong, V. W. S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021907 · Cited by 555
Emery, P., Zeidler, H., Kvien, T. K., Guslandi, M., Naudin, R., Stead, H., Verburg, K. M., Isakson, P. C., Hubbard, R. C., & Geis, G. S. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02332-6 · Cited by 543
Cannon, C. P., Curtis, S. P., FitzGerald, G. A., Krum, H., Kaur, A., Bolognese, J. A., Reicin, A. S., Bombardier, C., Weinblatt, M. E., van der Heijde, D., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69666-9 · Cited by 522
Kosinski, M., Zhao, S. Z., Dedhiya, S., Osterhaus, J. T., & Ware, J. E. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200007)43:7<1478::aid-anr10>3.0.co;2-m · Cited by 505
Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490
Felson, D. T., Anderson, J. J., Lange, M. L. M., Wells, G., & LaValley, M. P. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9 · Cited by 474
Laine, L., Harper, S., Simon, T., Bath, R., Johanson, J., Schwartz, H., Stern, S., Quan, H., & Bolognese, J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70334-3 · Cited by 474
Prevention of NSAID-induced gastroduodenal ulcers
Rostom, A., Dube, C., Wells, G. A., Tugwell, P., Welch, V., Jolicoeur, E., McGowan, J., Lanas, A., Rushton, E., & Shukla, T. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002296 · Cited by 470
SYMMONS, D. P. M., BARRETT, E. M., BANKHEAD, C. R., SCOTT, D. G. L., & SILMAN, A. J. (1994) · Rheumatology · doi:10.1093/rheumatology/33.8.735 · Cited by 464
Ehrich, E. W., Davies, G. M., Watson, D. J., Bolognese, J. A., Seidenberg, B. C., & Bellamy, N. (2000) · PubMed · Cited by 428
Sanmuganathan, P. S., Ghahramani, P., Jackson, P. R., Wallis, E. J., & Ramsay, L. E. (2001) · Heart · doi:10.1136/heart.85.3.265 · Cited by 410
Deeks, J. J., Smith, L. A., & Bradley, M. D. (2002) · BMJ · doi:10.1136/bmj.325.7365.619 · Cited by 369
Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease
Chenevard, R., Hürlimann, D., Béchir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000051361.69808.3a · Cited by 358
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use
Laine, L., Connors, L. G., Reicin, A., Hawkey, C. J., Burgos–Vargas, R., Schnitzer, T. J., Yu, Q., & Bombardier, C. (2003) · Gastroenterology · doi:10.1053/gast.2003.50054 · Cited by 355
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Konstam, M. A., Weir, M. R., Reicin, A., Shapiro, D., Sperling, R. S., Barr, E., & Gertz, B. J. (2001) · Circulation · doi:10.1161/hc4401.100078 · Cited by 352
Bensen, W. G., Fiechtner, J. J., McMillen, J. I., Zhao, W. W., Yu, S. S., Woods, E. M., Hubbard, R. C., Isakson, P. C., Verburg, K. M., & Geis, G. S. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.11.1095 · Cited by 348
Whelton, A., Fort, J. G., Puma, J. A., Normandin, D., Bello, A. E., & Verburg, K. M. (2001) · American Journal of Therapeutics · doi:10.1097/00045391-200103000-00003 · Cited by 334
Guidelines for the Management of Rheumatoid Arthritis
Anderson, L. G., Greene, J. M., Johnson, D. A., Simms, R. W., & Yood, R. A. (2002) · Cited by 325
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
GOLDSTEIN, J., SILVERSTEIN, F., AGRAWAL, N., HUBBARD, R., KAISER, J., MAURATH, C., VERBURG, K., & GEIS, G. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)00986-2 · Cited by 308
Graham, D. Y., Agrawal, N. M., Campbell, D. R., Haber, M. M., Collis, C., Lukasik, N. L., & Huang, B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.2.169 · Cited by 300
MacDonald, T. M., Morant, S. V., Robinson, G. C., Shield, M. J., McGilchrist, M. M., Murray, F. E., & McDevitt, D. G. (1997) · BMJ · doi:10.1136/bmj.315.7119.1333 · Cited by 296
Singh, G. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440130066007 · Cited by 287
Cannon, G. W., Caldwell, J. R., Holt, P., McLean, B., Seidenberg, B., Bolognese, J., Ehrich, E., Mukhopadhyay, S., & Daniels, B. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200005)43:5<978::aid-anr4>3.0.co;2-0 · Cited by 279
Rochon, P. A. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420020059007 · Cited by 277
Laine, L., Bombardier, C., Hawkey, C. J., Davis, B., Shapiro, D., Brett, C., & Reicin, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.36013 · Cited by 264
Day, R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.12.1781 · Cited by 264
Laine, L., Curtis, S. P., Cryer, B., Kaur, A., & Cannon, C. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60234-7 · Cited by 251
Hooper, L., Brown, T. J., Elliott, R., Payne, K., Roberts, C., & Symmons, D. (2004) · BMJ · doi:10.1136/bmj.38232.680567.eb · Cited by 244
Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis
Schumacher Jr, H. R., Boice, J. A., Daikh, D. I., Mukhopadhyay, S., Malmstrom, K., Ng, J., Tate, G. A., & Molina, J. (2002) · BMJ · doi:10.1136/bmj.324.7352.1488 · Cited by 238
White, W. B., Faich, G., Whelton, A., Maurath, C., Ridge, N. J., Verburg, K. M., Geis, G. S., & Lefkowith, J. B. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02265-2 · Cited by 230
Dequeker, J., Hawkey, C., Kahan, A., Steinbruck, K., Alegre, C., Baumelou, E., Begaud, B., Isomaki, H., Littlejohn, G., Mau, J., et al. (1998) · Rheumatology · doi:10.1093/rheumatology/37.9.946 · Cited by 227
Goldstein, J. L., Corréa, P., Zhao, W. W., Burr, A. M., Hubbard, R. C., Verburg, K. M., & Geis, G. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02303-6 · Cited by 199
DO YOUNG PATIENTS WITH DYSPEPSIA NEED INVESTIGATION?
Williams, B., Ellingham, J. H. M., Luckas, M., Dain, A., & Wicks, A. C. B. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90879-3 · Cited by 179
Renal Safety and Tolerability of Celecoxib, a Novel Cyclooxygenase-2 Inhibitor
Whelton, A., Maurath, C. J., Verburg, K. M., & Geis, G. S. (2000) · American Journal of Therapeutics · doi:10.1097/00045391-200007030-00004 · Cited by 167
Watson, D. J., Harper, S. E., Zhao, P.-L., Quan, H., Bolognese, J. A., & Simon, T. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.19.2998 · Cited by 164
Knee Pain Is the Malady—Not Osteoarthritis
Hadler, N. M. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-7-598 · Cited by 164
Safety of Meloxicam: A Global Analysis of Clinical Trials
Distel, M., Mueller, C., Bluhmki, E., & Fries, J. (1996) · Rheumatology · doi:10.1093/rheumatology/35.suppl_1.68 · Cited by 163
Scott, D. L., Shipley, M. E., Dawson, A., Edwards, S. M., Symmons, D. P. M., & Woolf, A. D. (1998) · Rheumatology · doi:10.1093/rheumatology/37.5.546 · Cited by 152
Effects of Celecoxib on Ambulatory Blood Pressure in Hypertensive Patients on ACE Inhibitors
White, W. B., Kent, J. D., Taylor, A. A., Verburg, K. M., Lefkowith, J. B., & Whelton, A. (2002) · Hypertension · doi:10.1161/01.hyp.0000014323.99765.16 · Cited by 149
COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk
Graham, D. J. (2006) · JAMA · doi:10.1001/jama.296.13.jed60058 · Cited by 147
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease
Mahadevan, U., Loftus, E. V., Tremaine, W. J., et al. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05608.x · Cited by 146
Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement
Bolognese, J. A., Schnitzer, T. J., & Ehrich, E. W. (2003) · Osteoarthritis and Cartilage · doi:10.1016/s1063-4584(03)00082-7 · Cited by 140
Schnitzer, T. J., Truitt, K. E., Fleischmann, R., Dalgin, P., Block, J. A., Zeng, Q., Bolognese, J., Seidenberg, B. C., & Ehrich, E. W. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80048-4 · Cited by 136
Reicin, A. S., Shapiro, D., SPERLING, R. S., Barr, E., & Yu, Q. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02201-9 · Cited by 136
A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
Matsumoto, A. K., Peña Melian, A., Mandel, D. R., McIlwain, H. H., BORENSTEIN, D. G., Zhao, P., Lines, C. R., Gertz, B. J., & Curtis, S. (2002) · PubMed · Cited by 131
The safety of celecoxib in patients with aspirin‐sensitive asthma
Woessner, K. M., Simon, R. A., & Stevenson, D. D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10426 · Cited by 131
Sigthorsson, G., Crane, R., Simon, T., Hoover, M., Quan, H., Bolognese, J., & Bjarnason, I. (2000) · Gut · doi:10.1136/gut.47.4.527 · Cited by 131
Jobanputra, P., Barton, P., Bryan, S., & Burls, A. (2002) · Health Technology Assessment · doi:10.3310/hta6210 · Cited by 126
Self-citationKimmel, S. E., Berlin, J. A., Reilly, M. P., Jaskowiak, J., Kishel, L., Chittams, J. L., & Strom, B. L. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.064 · Cited by 123
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis
Gottesdiener, K. M. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.9.1052 · Cited by 121
LEUNG, A. T., Malmström, K., Gallacher, A., Sarembock, B., Poór, G., Beaulieu, A. D., Castro, R. S., Sanchez, M., & Ng, J. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000282 · Cited by 117
Saag, K. G. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.10.1124 · Cited by 116
Maetzel, A., Krahn, M. D., & Naglie, G. (2003) · Arthritis Care & Research · doi:10.1002/art.11121 · Cited by 114
Bensen, W., Zhao, S.-X., Burke, T. A., Zabinski, R. A., Makuch, R., Maurath, C. J., Agrawal, N. M., & Geis, G. (2000) · PubMed · Cited by 113
Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal
Baigent, C., & Patrono, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10738 · Cited by 111
MacDonald, T. M., Morant, S. V., Goldstein, J. L., Burke, T. A., & Pettitt, D. (2003) · Gut · doi:10.1136/gut.52.9.1265 · Cited by 110
Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Lipsky, P. E., & Isakson, P. C. (1997) · PubMed · Cited by 109
Collantes‐Estévez, E., Curtis, S., Lee, K. W., Casas, N., McCarthy, T., Melian, A., Zhao, P., Rodgers, D. B., McCormick, C. L., Lee, M., et al. (2002) · BMC Family Practice · doi:10.1186/1471-2296-3-10 · Cited by 109
Silverfield, J. C., Kamin, M., Wu, S., & Rosenthal, N. R. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85024-x · Cited by 107
Makarowski, W. S., Zhao, W. W., Bevirt, T., & Recker, D. P. (2002) · Osteoarthritis and Cartilage · doi:10.1053/joca.2001.0510 · Cited by 107
Kivitz, A., Eisen, G. M., Zhao, W. W., Bevirt, T., & Recker, D. P. (2002) · PubMed · Cited by 106
Hunt, R. H., Harper, S. E., Callegari, P., Yu, C., Quan, H., Evans, J. K., James, C., Bowen, B. M., & Rashid, F. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01407.x · Cited by 106
Sikes, D. H., Agrawal, N. M., Zhao, W. W., Kent, J. D., Recker, D. P., & Verburg, K. M. (2002) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200210000-00011 · Cited by 101
Zhao, S. Z., McMillen, J. I., Markenson, J. A., Dedhiya, S. D., Zhao, W. W., Osterhaus, J. T., & Yu, S. S. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.16.1269.30879 · Cited by 96
Meta‐analysis of dyspepsia and nonsteroidal antiinflammatory drugs
Ofman, J. J., MacLean, C. H., Straus, W. L., Morton, S. C., Berger, M. L., Röth, E., & Shekelle, P. (2003) · Arthritis Care & Research · doi:10.1002/art.11192 · Cited by 90
Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study
Curtis, J. P., Wang, Y., Portnay, E. L., et al. (2003) · BMJ · doi:10.1136/bmj.327.7427.1322 · Cited by 83
Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction
Patel, T. N., & Goldberg, K. C. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.8.852 · Cited by 79
Truitt, K. E., SPERLING, R. S., Ettinger, W. H., Greenwald, M., DeTora, L. M., Zeng, Q., Bolognese, J. A., & Ehrich, E. W. (2001) · Aging Clinical and Experimental Research · doi:10.1007/bf03351533 · Cited by 78
Hawkey, C. J., Laine, L., Simon, T., Quan, H., Shingo, S., & Evans, J. (2003) · Gut · doi:10.1136/gut.52.6.820 · Cited by 77
Armstrong, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90003-8 · Cited by 76
Hunt, R. H., Bowen, B. M., Mortensen, E. R., Simon, T. J., James, C., Cagliola, A., Quan, H., & Bolognese, J. A. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00470-8 · Cited by 75
Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs
Hawkey, C. J., Karrasch, J. A., Szczepanski, L., et al. (1999) · Survey of Anesthesiology · doi:10.1097/00132586-199906000-00059 · Cited by 73
Cannon, C. P., Curtis, S., Bolognese, J. A., & Laine, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.05.024 · Cited by 69
Wojtulewski, J. A., Schattenkirchner, M., Barceló, P., Loët, X. L., Bevis, P. J. R., Bluhmki, E., & Distel, M. (1996) · Rheumatology · doi:10.1093/rheumatology/35.suppl_1.22 · Cited by 69
Immunologic tolerability profile of celecoxib
Patterson, R., Bello, A. E., & Lefkowith, J. B. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)87238-0 · Cited by 66
Gibofsky, A., Williams, G. W., McKenna, F., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11330 · Cited by 66
Williams, G. W., Hubbard, R. C., Yu, S. S., Zhao, W. W., & Geis, G. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80004-7 · Cited by 65
Kamath, C. C., Kremers, H. M., Vanness, D. J., O’Fallon, W. M., Cabanela, R. L., & Gabriel, S. E. (2003) · Value in Health · doi:10.1046/j.1524-4733.2003.00215.x · Cited by 64
Kivitz, A., Nayiager, S., Schimansky, T., Gimona, A., Thurston, H. J., & Hawkey, C. J. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01956.x · Cited by 59
Hawkey, C. J., Laine, L., Harper, S. E., Quan, H. U. I., Bolognese, J. A., Mortensen, E. R., & For The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01007.x · Cited by 57
Sheen, C. L., Dillon, J. F., Bateman, D. N., Simpson, K. J., & MacDonald, T. M. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.701 · Cited by 57
Rofecoxib for rheumatoid arthritis
Garner, S. E., Fidan, D., Frankish, R. R., Judd, M., Towheed, T., Tugwell, P., & Wells, G. A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003685.pub2 · Cited by 56
Pavelká, K. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg359 · Cited by 56
Fries, J. F., & Bruce, B. (2003) · PubMed · Cited by 55
McKenna, F., Weaver, A., Fiechtner, J. J., Bello, A. E., & Fort, J. G. (2001) · JCR Journal of Clinical Rheumatology · doi:10.1097/00124743-200106000-00004 · Cited by 49
Rabeneck, L., Wristers, K., Goldstein, J. L., Eisen, G. M., Dedhiya, S. D., & Burke, T. A. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05419.x · Cited by 48
Pellissier, J. M. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80092-8 · Cited by 47
Geusens, P., Truitt, K. E., Sfikakis, P. P., Zhao, P. L., DeTora, L. M., Shingo, S., Lau, C. S., Kalla, A. A., & Tate, G. (2002) · Scandinavian Journal of Rheumatology · doi:10.1080/030097402320318431 · Cited by 45
Bianchi, M., & Broggini, M. (2003) · Drugs · doi:10.2165/00003495-200363001-00006 · Cited by 44
Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac
Goldstein, J. L., Eisen, G. M., Burke, T. A., Pena, B. M., Lefkowith, J. B., & Geis, G. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01219.x · Cited by 40
Gertz, B. J., Krupa, D. A., Bolognese, J. A., SPERLING, R. S., & Reicin, A. S. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000354 · Cited by 40
Ehrich, E. W., Bolognese, J. A., Watson, D. J., & Kong, S. (2001) · PubMed · Cited by 37
Lisse, J., Espinoza, L., Zhao, S., Dedhiya, S. D., & Osterhaus, J. T. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.3.m167 · Cited by 36
Kivitz, A., Greenwald, M., Cohen, S. B., Polis, A. B., Najarian, D. K., Dixon, M. E., Moidel, R. A., Green, J. A., Baraf, H. S. B., Petruschke, R. A., et al. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52201.x · Cited by 33
Are COX-2 selective inhibitors nephrotoxic?
Mj, D. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70274-5 · Cited by 33
COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.
Herrera-Acosta, J., Tapia, E., Sánchez-Lozada, L. G., Franco, M., Striker, L. J., Striker, G. E., & Rodríguez, I. B. (2002) · PubMed · Cited by 32
Hawkey, C. J., Farkouh, M. E., Gitton, X., Ehrsam, E., Huels, J., & Richardson, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02026.x · Cited by 32
Bae, S. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/keg029 · Cited by 30
Moore, R. A., Phillips, C. J., Pellissier, J. M., & Kong, S. X. (2001) · Journal of Medical Economics · doi:10.3111/200104001017 · Cited by 23
Global Analysis of Gastrointestinal Safety of a New Nsaid, Meloxicam
Distel, M., Mueller, C., & Bluhmki, E. (1997) · Springer eBooks · doi:10.1007/978-94-011-5394-2_19 · Cited by 22
The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs
Curtis, J. P., & Krumholz, H. M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.01.001 · Cited by 20
The different patterns of blood pressure elevation by rofecoxib and nabumetone
Reitblat, T., Zamir, D., Estis, L., Priluk, R., Drogenikov, T., & Viskoper, J. R. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001411 · Cited by 18
(2005) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1300/j354v19n04_15 · Cited by 17
Liang, T.-H., & Hsu, P. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001866 · Cited by 16
Comparison of etodolac and diclofenac in osteoarthritis of the knee.
Am, G., Aa, V., & Samara, A. M. (1993) · PubMed · Cited by 13
Lexchin, J. (2002) · PubMed Central · Cited by 9
Gravellese (2000) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200002)43:2 · Cited by 2
Xu, J. (2002) · Zhōnghuá yàoxué zázhì · Cited by 1
Meloxicam vs nabumetone in treating osteoarthritis: a double-blind, control study
Xu, J. (2002) · Chinese Journal of New Drugs and Clinical Remedies · Cited by 1
Cited by
Scott, D. L., Wolfe, F., & Huizinga, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,013
Loveday, H. P., Wilson, J. A., Pratt, R. J., Golsorkhi, M., Tingle, A., Bak, A., Browne, J., Prieto, J., & Wilcox, M. (2014) · Journal of Hospital Infection · doi:10.1016/s0195-6701(13)60012-2 · Cited by 1,621
A review of the biomaterials technologies for infection-resistant surfaces
Campoccia, D., Montanaro, L., & Arciola, C. R. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.089 · Cited by 1,358
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
Breen, L., & Phillips, S. M. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-68 · Cited by 576
Metadata
- Authors
- Chen, Y., Jobanputra, P., Barton, P., Bryan, S., Fry-Smith, A., Harris, G., & Taylor, R.
- Venue
- Health Technology Assessment
- Published
- 2008-04
- Volume
- 12
- Issue
- 11
- Pages
- 1-278, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1988145586
- Cited by
- 339
- References
- 131
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.